Eli Lilly and Company
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Eli Lilly and Company
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $65.179B
Eli Lilly's business model is characterized by substantial, high-risk R&D bets with binary outcomes. The company funds its extensive pipeline through the lucrative sales of specialized treatments in diabetes, oncology, and immunology. Its current astronomical valuation is entirely dependent on maintaining its duopoly with Novo Nordisk in the GLP-1 (weight loss and diabetes) drug market.
Lilly is investing heavily in manufacturing capacity, next-generation obesity and diabetes drugs, oncology, immunology, neuroscience, and external collaborations to extend growth beyond the first tirzepatide wave.
They operate a massive pharmaceutical empire. They spend billions researching new chemical compounds. If the FDA approves a drug, the US government grants Eli Lilly a massive, absolute 20-year patent monopoly, allowing them to charge tens of thousands of dollars per patient.
This is their absolute gold mine. It is a highly revolutionary injectable drug (tirzepatide). Mounjaro treats diabetes, while Zepbound is approved for massive weight loss. Demand is so incredibly high that it routinely causes massive global shortages, generating billions in instant revenue.
They spun it off. Eli Lilly refuses to make cheap, 'Over-The-Counter' (OTC) drugs because the profit margins are terrible. They focus 100% of their massive resources strictly on incredibly complex, highly expensive prescription drugs for cancer, Alzheimer's, and diabetes.
The US subsidizes the world. In Europe, the government legally dictates the maximum price Eli Lilly can charge. In the US, Eli Lilly can legally charge whatever the market will bear. The massive profits made in America fund their entire global R&D budget.
The 'Patent Cliff'. It is catastrophic. When the patent for Prozac expired, generic manufacturers legally copied the exact chemical formula and sold it for pennies. Eli Lilly lost 80% of Prozac's massive revenue almost overnight, forcing them to constantly invent new drugs to survive.